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Results: The incidence of stroke in seniors with Ͼ60% carotid stenosis with best medical management at the time in the Asymptomatic Carotid Arteriosclerotic Study was 11% and should be at least that with no discovery or management. Screening 18,446 seniors in the AVA program yielded 7.4% with possible Ͼ60% carotid stenosis, far more than the 1% figure used by the USPSTF in recommending against screening. Since a stroke rate of Ͻ2% is widely available with CEA, 200,000 strokes could be prevented by screening the senior Medicare population. The cost of a stroke averages $145,000 and the cost of carotid screening, evaluation, and management to prevent one stroke is $82,193 resulting in a saving of $64,807. Carotid screening of seniors could save over 13 billion dollars annually for the Medicare system.
Conclusions: Stroke remains the leading cause of disability, and the 3rd leading cause of death. Since treatment of stroke is less than ideal, emphasis on primary stroke prevention is appropriate, but strokes cannot be reduced if the silent leading immediate cause of strokes, carotid artery disease, is not recognized and managed. Management by the best means for the patient-CEA, CAS, or medically-has to be better than no recognition and no management. Carotid screening should be done. Since vascular surgeons are the most knowledgeable in carotid disease and application of the treatment options, screening nationally for carotid disease should be presented to and discussed by the SVS.
Author Disclosures: G. S. Lavenson: Nothing to disclose. Results: 201 AVFs were created in 171 patients (mean age 63.7ϩ/Ϫ 9.5; male 99%; non-white 48%; active dialysis 55%). 45% were wrist fistulas, 54% upper arm, 31% re-do. Older groups had more CAD (19% of Ͻ60, versus 51% of 60-75, versus 55% of Ͼ75; p Ͻ 0.001) and more CHF (12% versus 35% versus 45%; p Ͻ 0.001). There were no differences by age group in diabetes, hypertension, PAD, BMI, vein diameter, AVF location, re-do or dialysis catheter status. Mean follow-up was 32 months (range 6-79).
RR9.

Functional Outcome of Arteriovenous Fistula
32% of AVFs were in use at 6 months. Success decreased with age: 50% in patients Ͻ60, versus 25% in 60-75, versus 21% in those Ͼ75 (log-rank test, p ϭ 0.007). A multivariable Cox model identified age as the sole independent predictor of outcome (HR 0.96, 95% CI 0.93-0.99). 54% of AVFs were used eventually, more frequently in the younger group (68% versus 44% and 47%; log-rank test, p ϭ 0.018). 14% of patients Ͻ60 died before the AVF was ever used, compared with 30% and 34% in the older groups. Median patient survival was 85, 53, and 26 months, respectively (log-rank test, pϭ 0.002).
Conclusions: A functional AVF is harder to achieve in older Veterans, whose median survival is limited. Prosthetic AV grafts may offer superior permanent dialysis access for many of these patients.
Author Disclosures: F. Bech: Nothing to disclose; E. Gyang: Nothing to disclose. Objectives: Most of the arteriovenous hemodialysis grafts fail within eighteen months post-implantation, most commonly due to intimal hyperplasia at the venous anastomosis. The aim of our study was to compare balloon angioplasty versus bare metal stent placement in the treatment of venous anastomotic stenosis following thrombectomy of upper arm straight arteriovenous hemodialysis grafts.
RR10.
Balloon Angioplasty versus Stent Placement in the Treatment of Venous Anastomotic Stenoses of Hemodialysis Grafts Following Surgical Thrombectomy
Methods: Between 2/2007 and 12/2010, 61 patients with a first-time thrombosis of an upper arm straight arteriovenous hemodialysis graft were admitted to our hospital. Twenty-eight (46%) of these patients, treated before 6/2008, underwent thrombectomy plus balloon angioplasty of the venous anastomosis (group A), whereas the rest 33 (54%) patients, treated after 7/2008, underwent graft thrombectomy plus angioplasty with self-expanding nitinol stent placement (Group B). Primary patency, defined as the time period from graft thrombectomy plus angioplasty to the next graft failure, was estimated using Kaplan-Meier analysis and compared between the two groups with the log-rank test.
Results: In group A, primary patency was 32% at 3 months, 24% at 6 months and 14% at 12 months. The respective values in group B were 85%, 63% and 49% (Figure) . Primary patency was significantly better in group B than in group A (pϭ0.001, log rank test). Median patency in group A was 2 months, whereas in group B it was 12 months.
Conclusions: Graft thrombectomy plus angioplasty with self-expanding nitinol stent placement provides significantly higher patency rates compared with thrombectomy plus plain balloon angioplasty of the venous anastomosis.
